Efficacy and Safety of Meropenem–Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis

INTRODUCTION: Infections due to Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are associated with increased morbidity and high mortality. Meropenem–vaborbactam (MV) is a novel β-lactam/β-lactamase inhibitor combination active against KPC-producing Enterobacteriaceae. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Bassetti, Matteo, Giacobbe, Daniele Roberto, Patel, Niki, Tillotson, Glenn, Massey, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824459/
https://www.ncbi.nlm.nih.gov/pubmed/31098989
http://dx.doi.org/10.1007/s12325-019-00981-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824459/
https://www.ncbi.nlm.nih.gov/pubmed/31098989
http://dx.doi.org/10.1007/s12325-019-00981-y

Ejemplares similares